Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Covington
US Department of Justice
QuintilesIMS
Cipla
Chinese Patent Office
Johnson and Johnson
UBS
Daiichi Sankyo

Generated: April 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,546,608

« Back to Dashboard

Which drugs does patent 8,546,608 protect, and when does it expire?

Patent 8,546,608 protects NINLARO and is included in one NDA.

This patent has thirty-four patent family members in thirty countries.
Summary for Patent: 8,546,608
Title:Proteasome inhibitors and methods of using the same
Abstract: The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.
Inventor(s): Bernardini; Raffaella (Calci, IT), Bernareggi; Alberto (Concorezzo, IT), Cassara; Paolo G. (Monza, IT), Chatterjee; Sankar (Wynnewood, PA), D'Arasmo; Germano (Novate Milanese, IT), De Munari; Sergio (Milan, IT), Ferretti; Edmondo (Ravenna, IT), Iqbal; Mohamed (Malvern, PA), Menta; Ernesto (Cernusco sul Naviglio, IT), Messina McLaughlin; Patricia A. (Glen Mills, PA), Oliva; Ambrogio (Saronno, IT)
Assignee: Cephalon, Inc. (Frazer, PA)
Application Number:13/249,738
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 8,546,608

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Millennium Pharms NINLARO ixazomib citrate CAPSULE;ORAL 208462-001 Nov 20, 2015 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Millennium Pharms NINLARO ixazomib citrate CAPSULE;ORAL 208462-002 Nov 20, 2015 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Millennium Pharms NINLARO ixazomib citrate CAPSULE;ORAL 208462-003 Nov 20, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,546,608

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,058,262 Proteasome inhibitors and methods of using the same ➤ Try a Free Trial
9,233,115 Proteasome inhibitors and methods of using the same ➤ Try a Free Trial
7,576,206 Proteasome inhibitors and methods of using the same ➤ Try a Free Trial
7,915,236 Proteasome inhibitors and methods of using the same ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,546,608

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 045381 ➤ Try a Free Trial
Argentina 095249 ➤ Try a Free Trial
Austria 438650 ➤ Try a Free Trial
Australia 2004268946 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Argus Health
Moodys
Julphar
US Army
Mallinckrodt
Farmers Insurance
Deloitte
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.